Beam Therapeutics Inc. (BEAM)
Last updated: 2026-10-20 23:26:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Beam Therapeutics Inc. (BEAM) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $24.93, with a market capitalization of $2.42B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $20.23 to $38.26. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$2.42B | |
$24.00 | |
$138.52 | |
$13.00 | |
$24.19 | |
1.04M | |
1.81M | |
-- | |
$38.26 | |
$20.23 | |
-- | |
-- |
Beam Therapeutics Inc. (BEAM) After-Hours Stock Price
Beam Therapeutics Inc. (BEAM) is trading at $24.73 in after-hours trading as of 2026-10-20 23:25:00, up 2.21% ($0.54) from the regular-session close of $24.19.
After-hours trading shows how investors are pricing BEAM after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Beam Therapeutics Inc. (BEAM) 7-Day Stock Price Change
Over the past seven days, Beam Therapeutics Inc. (BEAM) moved from $25.70 to $24.93, representing a decline of 2.99% ($0.77).
The stock traded between $23.16 and $26.23 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 1.61 million shares, down versus the previous seven-day period, indicating lower trading activity.
BEAM 52-Week Price Position
Position in Range: 26.1%
BEAM is currently trading at $24.93, placing it 26.1% of the way from its 52-week low of $20.23 to its 52-week high of $38.26. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Beam Therapeutics Inc. (BEAM)?
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
Beam Therapeutics Inc. Information
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 540 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Beam Therapeutics Inc. (BEAM) Stock on MEXC
Eligible investors can buy real shares of Beam Therapeutics Inc. (BEAM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Beam Therapeutics Inc. (BEAM) stock price today?
2.Is BEAM stock going up or down today?
3.What is BEAM pre-market price?
4.What is BEAM after-hours price?
5.Is BEAM stock trading now?
6.Where does BEAM sit relative to its 52-week high and low?
7.What sector is Beam Therapeutics Inc. in?
8.What is Beam Therapeutics Inc.'s market capitalization and where is it listed?
9.How is BEAM valued in terms of P/E ratio and EPS?
10.Does Beam Therapeutics Inc. pay a dividend?
Explore More US Stocks
Search Stocks
BEAM Stock Calculator
Estimate the value between BEAM shares and USD.
BEAM Shares to USD
1.00 BEAM shares = 24.932 USD
Calculations are estimates based on the latest available price and are for reference only.


